Institut du Cancer de Montpellier - Val d'Aurelle
icm.unicancer.frTotal trials
141
Active
63
Phase 3
8
Total enrollment
38,529
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 27 of 27 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Regorafenib | — | — | — | — | 2 | ||
| Irinotecan | — | — | — | — | 2 | ||
| Induction chemotherapy - modified FOLFIRINOX regimen | — | — | — | — | — | 1 | |
| oxaliplatin | — | — | — | — | 7 | ||
| Oxaliplatin LBM | — | — | — | — | — | 1 | |
| standard radiotherapy with chemotherapy | — | — | — | — | — | 1 | |
| GEMBRAX/FOLFIRINOX Arm A | — | — | — | — | — | 1 | |
| FOLFIRINOX Arm B | — | — | — | — | — | 1 | |
| Pravastatin | — | — | — | — | — | 1 | |
| Intraperitoneal chemotherapy during surgery | — | — | — | — | — | 1 | |
| Gabrinox | — | — | — | — | — | 1 | |
| Lutathera | — | — | — | — | — | 1 | |
| Biological collection | — | — | — | — | — | 4 | |
| Blood sample | — | — | — | — | — | 3 | |
| Blood and tissue sampling | — | — | — | — | — | 1 | |
| Blood sample and tissue sample | — | — | — | — | — | 1 | |
| Blood sampling C1 | — | — | — | — | — | 1 | |
| Biological/Vaccine: Blood sample and tissue sample | — | — | — | — | — | 1 | |
| Blood sampling | — | — | — | — | — | 1 | |
| Blood sampling C3 | — | — | — | — | — | 1 | |
| Blood sampling C4/7/10/13 | — | — | — | — | — | 1 | |
| Blood sampling C5 | — | — | — | — | — | 1 | |
| Blood sampling C6 | — | — | — | — | — | 1 | |
| Blood sampling C8 | — | — | — | — | — | 1 | |
| Blood sampling C9 | — | — | — | — | — | 1 | |
| Blood sampling C11 + FFPE | — | — | — | — | — | 1 | |
| Blood sampling C12 | — | — | — | — | — | 1 |
Next readouts
- 2017-08-31
- 2022-05-31
- 2022-07-28
- 2024-09-04
- 2026-01-31
- 2026-05
- 2026-05-29
- 2026-08
- 2026-10
- 2026-12
Top conditions
- Breast Cancer40
- Cancer8
- Colorectal Cancer7
- Rectal Cancer6
- Prostate Cancer5
- Head and Neck Cancer5
- Metastatic Colorectal Cancer4
- Glioma4
Frequently asked questions about Institut du Cancer de Montpellier - Val d'Aurelle
- How many clinical trials does Institut du Cancer de Montpellier - Val d'Aurelle have on ClinicalTrials.gov?
- Institut du Cancer de Montpellier - Val d'Aurelle is listed as the lead sponsor on 141 clinical trials in ClinicalTrials.gov, 63 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Institut du Cancer de Montpellier - Val d'Aurelle's trials are in Phase 3?
- 8 of Institut du Cancer de Montpellier - Val d'Aurelle's trials are in Phase 3, spread across 27 active drug programs.
- What therapeutic areas does Institut du Cancer de Montpellier - Val d'Aurelle focus on?
- Institut du Cancer de Montpellier - Val d'Aurelle's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Colorectal Cancer, Rectal Cancer, Prostate Cancer.
- When are Institut du Cancer de Montpellier - Val d'Aurelle's next clinical trial readouts?
- Institut du Cancer de Montpellier - Val d'Aurelle has 10 upcoming primary-completion readouts tracked here; the soonest is “Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)”, expected around 2017-08-31.